MAP2K2 and melanoma: In 177 of 253 (70.0%) melanoma patients, somatic mutations in the analyzed genes were detected by the biochip assay (Table 2): 129 (51.0%) BRAF, 45 (17.8%) NRAS, 6 (2.4%) KIT, 4 (1.6%) GNAQ, 2 (0.8%) GNA11, 2 (0.8%) MAP2K1 and none of MAP2K2. The biochip allows the detection of only the most common somatic mutations, which are listed in Table 2.